Sanofi moved to stop pursuing approval for amlitelimab in atopic dermatitis, formally halting development of the troubled immune drug that had been positioned as a potential successor to Dupixent. The decision marks another pipeline setback for Sanofi and follows analysts’ expectations that the company would shift to “strategic action” to refresh its remaining immunology roadmap. The halt reduces near-term optionality in a crowded eczema market and signals that the drug’s benefit-risk bar was not met to justify a regulatory push in the current program structure. In practice, the company’s next steps are likely to center on reprioritizing resources toward assets with clearer probability of clinical and regulatory success. For the field, the move is a reminder that even late-stage immune-modulator bets can fail to translate into meaningful improvements versus current standard therapies.